BACKGROUND: Lung transplant recipients develop @entity2 more commonly than the general population. The best treatment approach for these @entity1 is unclear. The goal of this study is to evaluate treatment outcomes in this population. METHODS: We used the Cleveland Clinic lung transplant database to identify @entity1 diagnosed with @entity2 at the time of or after lung transplant. @entity2 -related data were retrospectively reviewed. RESULTS: Among 847 @entity1 underwent lung transplant between 2005 and 2013, 17 (2%) were diagnosed with @entity2 and included. Median age was 61 (range, 48-70) years. Majority were stage I/II (n=11), one had stage IIIA, five had stage IV. @entity1149 ( @entity1149 ) were more common than @entity151 ( @entity151 ) (n=15 vs. 2). Curative treatment was performed as lobectomy in native lung (n=1), and radiation in transplanted lung (n=2). Chemotherapy was given in 10 @entity1 , primarily @entity3003 -based doublets with @entity1205 , pemetrexed, or @entity2879 . Six of these received palliative chemotherapy for either @entity3 at diagnosis (n=3) or recurrence after early stage disease (n=3). Except for one @entity1 with complete response, all others had @entity74 following palliative chemotherapy. Overall, @entity1 who received chemotherapy had a median survival of 7.5 months from the initiation of chemotherapy, but 30% developed grade 5 @entity295 . Median survival for stage I-IIIA and stage IV were 23.2 and 2.5 months respectively. CONCLUSIONS: @entity2 in lung transplant recipients carries various clinical courses. @entity1 with @entity3 have substantial @entity137 from chemotherapy and poor survival. Early stage @entity1 should be offered treatment with modified dosages to decrease the risk of severe @entity137 .

XXXX treatment outcomes in recipients of lung transplant.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer', 'Transplant and lung cancer', 'lung cancer'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic disease'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small cell lung cancer'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity2 :: (MESH:D008175,Disease) :: ['Lung cancer']
